Ryan et al have recently written a useful article on managing dyslipidaemia for the primary prevention of cardiovascular disease1. They consider the evidence regarding the benefits and harms of statin medication and conclude that, "At present we have no way of knowing who will experience the benefits or harms of statin therapy before starting medication". We would like to highlight to readers a couple of our papers which have addressed this question2. In 2010, we published a large population-based cohort study using the QResearch database (www.qresearch.org) to individualise the risks of statins in men and women in England. We also produced a web calculator www.qintervention.org which allows an individual calculate these risks. In 2018, we published an update to the QDiabetes-2018 algorithm which, for the first time, quantifies the risk of developing diabetes among patients prescribing statins, taking account of their other risk factors3. The web calculator can be found here www.qdiabetes.org/2018. Lastly, we would also like to highlight the publication of QRISK3 https://qrisk.org/three/index.php last year in the BMJ4 which will replace QRISK2 later this year.
